Home   >  
Angiogenesis/Protein Tyrosine Kinase
c Met

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

c Met

Chemical Structure Cat. No. Product Name CAS No.
SOMG-833 HCl Chemical Structure
BCP49025 SOMG-833 HCl 1268264-10-3
SOMG-833 HCl is a selective c-MET inhibitor that acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.
Fosgonimeton Chemical Structure
BCP46997 Fosgonimeton 2093305-05-4
Fosgonimeton is a hepatocyte growth factor receptor agonist.
Ningetinib Chemical Structure
BCP46143 Ningetinib 1394820-69-9
Ningetinib is a novel tyrosine kinase inhibitor, targeted at c-Met, Axl, VEGFR-2, Mer and Flt3.
JNJ-38877605 Chemical Structure
BCP44121 JNJ-38877605 943540-74-7
JNJ-38877618 is a hepatocyte growth factor receptor (HGFR; MET; c-Met) inhibitor potentially for the treatment of solid tumours.
Norleual Chemical Structure
BCP41927 Norleual 334994-34-2
Norleual, an angiotensin IV analog, competitively inhibited the binding of HGF to its receptor c-Met in mouse liver membranes. It is also an AT4 receptor antagonist, which disrupts LTP stabilization.
PF-04217903 phenolsulfonate Chemical Structure
BCP36115 PF-04217903 phenolsulfonate 1159490-85-3
PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor. It shows more than 1,000-fold selectivity relative to 208 kinases.PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met.
ARQ 197 Chemical Structure
BCP28549 ARQ 197 1000873-98-2
ARQ-197 is a selective inhibitor of the c-Met receptor tyrosine kinase
S49076 HCl Chemical Structure
BCP35053 S49076 HCl 1265965-19-2
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
Bozitinib Chemical Structure
BCP34901 Bozitinib 1440964-89-5
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability.
TAS-115 mesylate Chemical Structure
BCP34015 TAS-115 mesylate 1688673-09-7
TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
123下一页末页共 53 条记录 1 / 6 页